Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

For more audio journalism and storytelling, download New York Times Audio, a new iOS app available for news subscribers. transcript This transcript was created using speech recognition software ...

Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the ...

Junshi has conducted more than 40 company-sponsored clinical studies of the therapy. Credit: PeopleImages.com – Yuri A/Shutterstock. Shanghai Junshi Biosciences and its subsidiary TopAlliance ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...

but the investigators were allowed to withhold a dosage escalation if there were concerns about safety or tolerability. During the treatment phase, 34% of patients in both the duloxetine and ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement . That compared with a 17.5% ...

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement. That compared with a 17.5% ...

Fol­low­ing the poor­er-than-hoped per­for­mance of Ca­griSe­ma last month, No­vo Nordisk need­ed an em­phat­ic clin­i­cal suc­cess with its high-dose ver­sion of We­govy. The … ...